Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13090559 | 1.00 | REN (0.49) | RENCYP3A4SMPD1HDAC1HDAC8 | |
| SCHEMBL9907043 | 0.87 | REN (0.46) | RENCYP3A4 | |
| SCHEMBL9907045 | 0.87 | REN (0.60) | REN | |
| SCHEMBL13090555 | 0.87 | REN (0.46) | RENCYP3A4 | |
| SCHEMBL13090547 | 0.86 | REN (0.46) | REN | |
| SCHEMBL9907039 | 0.86 | REN (0.46) | REN | |
| SCHEMBL9907036 | 0.77 | REN (0.48) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL5020090 | 0.76 | REN (0.72) | REN | |
| SCHEMBL13206687 | 0.75 | REN (0.46) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL862115 | 0.74 | REN (0.59) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198465-B2 | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2012-06-12 | — | — | US | disclosed |
| US-8198465-B2 | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2012-06-12 | — | — | US | disclosed |
| US-20100267965-A1 | 3-Alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors | NODEN PHARMA DESIGNATED ACTIVITY COMPANY (IE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267965-A1 | 3-Alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors | NODEN PHARMA DESIGNATED ACTIVITY COMPANY (IE) | 2010-10-21 | — | — | US | disclosed |
| US-7772405-B2 | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2010-08-10 | — | — | US | disclosed |
| US-7772405-B2 | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2010-08-10 | — | — | US | disclosed |
| US-20080262246-A1 | 3-Alkyl-5- (4-Alkyl-5-Oxo-Tetrahydrofutr An -2-Yl) Pyrrolidin-2-One Derivatives As Intermediates In The Synthesis Of Renin Inhibitors | NODEN PHARMA DESIGNATED ACTIVITY COMPANY (IE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262246-A1 | 3-Alkyl-5- (4-Alkyl-5-Oxo-Tetrahydrofutr An -2-Yl) Pyrrolidin-2-One Derivatives As Intermediates In The Synthesis Of Renin Inhibitors | NODEN PHARMA DESIGNATED ACTIVITY COMPANY (IE) | 2008-10-23 | — | — | US | disclosed |
| WO-2007045420-A2 | 3-ALKYL-5- (4-ALKYL-5-OXO-TETRAHYDROFUTRAN-2-YL) PYRROLIDIN-2-ONE DERIVATIVES AS INTERMEDIATES IN THE SYNTHESIS OF RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267965-A1 | 3-Alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors | REN, AGTR2, AGTR1 | REN 1/4885CYP3A4 67/4885SMPD1 4511/4885 |
| US-20080262246-A1 | 3-Alkyl-5- (4-Alkyl-5-Oxo-Tetrahydrofutr An -2-Yl) Pyrrolidin-2-One Derivatives As Intermediates In The Synthesis Of Renin Inhibitors | REN, AGTR2, AGTR1 | REN 1/4885CYP3A4 144/4885SMPD1 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.